The $3 million funding recommendation from the Department of Defense is a significant financial boost for Plus Therapeutics, directly supporting the expansion of its clinical trial for pediatric brain cancer. This funding not only aids in the development of its novel therapeutic, Rhenium (186Re) Obisbemeda, but also extends the company's financial runway, reducing immediate financial pressure and potentially enhancing investor confidence in the company's stability and growth prospects. Given the direct financial benefit and the support for a key area of the company's research and development, this news is likely to be viewed positively by investors, potentially leading to a short-term uptick in PSTV's stock price.